Atlas Trials

Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours

Clinical trial NCT00716417 · COMPLETED

Trial details

NCT number
NCT00716417
Sponsor
Boehringer Ingelheim
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Neoplasms
Start date
2008-07-01
Primary completion
2010-07-01
Enrollment
47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.